An increased CXCL10 and its corresponding receptor, CXCR3, are positively associated with malignant melanoma [55], ovarian carcinoma [56], multiple myeloma [57], B-cell lymphoma [58], and basal cell carcinoma [59]. Here, CXCR3 is linked to ovarian carcinoma.